First-in-human randomised placebo-controlled dose-escalation trial of oral Shigella-ETEC vaccine CVD 1208S-122: 10⁸ CFU was well tolerated (6/6), but 4/6 given 10¹⁰ CFU had fever or diarrhoea; shed strains were genetically stable and immune responses were seen.
RCT
Chen et al. Evaluation of the Safety, Genetic Stability, and Immunogenicity of an Attenuated Shigella Live Vector Expressing Enterotoxigenic Escherichia coli Antigens, Vaccine Strain CVD 1208S-122